Key Findings:  This overview covers the most recent understanding of the pharmacokinetics and novel mechanisms of action of non-psychoactive cannabinoids. There is evidence of the positive effects of cannabidiol in treating inflammation, diabetes, cancer, and neurodegenerative diseases. Additional attention is paid to Delta(9)-tetrahydrocannabivarin, a CB1 antagonist having possible usefulness in treating epilepsy and obesity.
Type of Study:  Meta-analysis
Study Result:  Positive
Study Location(s):  Italy
Year of Pub:  2009
Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source:  Unspecified
Receptors Studied:  CB1, CB2